| Literature DB >> 28217176 |
Soraia Rosa1, Chris Connolly1,2, Giuseppe Schettino2, Karl T Butterworth1, Kevin M Prise1.
Abstract
There has been growing interest in the use of nanomaterials for a range of biomedical applications over the last number of years. In particular, gold nanoparticles (GNPs) possess a number of unique properties that make them ideal candidates as radiosensitizers on the basis of their strong photoelectric absorption coefficient and ease of synthesis. However, despite promising preclinical evidence in vitro supported by a limited amount of in vivo experiments, along with advances in mechanistic understanding, GNPs have not yet translated into the clinic. This may be due to disparity between predicted levels of radiosensitization based on physical action, observed biological response and an incomplete mechanistic understanding, alongside current experimental limitations. This paper provides a review of the current state of the field, highlighting the potential underlying biological mechanisms in GNP radiosensitization and examining the barriers to clinical translation.Entities:
Keywords: Cancer therapy; Gold nanoparticle; Radiation therapy; Radiosensitization
Year: 2017 PMID: 28217176 PMCID: PMC5288470 DOI: 10.1186/s12645-017-0026-0
Source DB: PubMed Journal: Cancer Nanotechnol ISSN: 1868-6958
Fig. 1Photon mass energy absorption coefficients of soft tissue and gold. The ratio of the mass energy absorption coefficients is shown as a function of photon energy (Hubbell and Seltzer 1996)
Fig. 2Comparison of predicted and observed values of dose enhancement for gold nanoparticles at both megavoltage and kilovoltage energies. “Increase in physical dose” here refers to the ratio of the additional dose deposited by X-rays in the system due to the addition of GNPs to that which would be deposited in the absence of gold. The observed data in this figure are dose modification results from in vitro experiments, while the predicted dose increase is based on the gold concentrations and X-ray energies used. The dashed line shows the trend which would be followed if the sensitizer enhancement ratio directly followed predicted increases in physical dose (Butterworth et al. 2013)
Fig. 3Schematic illustration of the photoelectric, Compton and Auger Effects. The Compton effect is represented in blue, the photoelectric effect in green and the Auger effect in red as described above
Fig. 4Schematic representation of the biological mechanisms involved in GNP radiosensitization. GNPs influence oxidative stress, DNA damage, cell cycle and bystander effects
Summary of radiosensitizing experimental data obtained with ionizing radiation and gold nanoparticles
| Author | Size (nm) | Concentration | Surface coating | Cell model | Source energy | DEF/effect |
|---|---|---|---|---|---|---|
| In vitro | ||||||
| Bobyk et al. ( | 1.9 | 10 mg/ml, 15 min | Thiol | F98 glioma cells | 50 keV, 6 Gy | Sensitization ratio of 1.92 for 1.9 nm particles and 1.4 for 15 nm particles |
| Butterworth et al. ( | 1.9 | 10, 100 µg/ml | Thiol | AGO-1552B | 160 kVp | 1.97 |
| Chang et al. ( | 13 | 10 nM | Citrate | B16F10 | 6 MV e− | Significant decrease in SF @ 8 Gy |
| Chattopadhyay et al. ( | 30 | 2.4 mg/ml | PEG, HER2 targeted | MDA-MB-231 | 100 kVp | 1.6 (targeted) |
| Chen et al. ( | 28 | 36 µg/ml | BSA | U87 | 160 kVp | 1.37 |
| Chithrani et al. ( | 14 | 7 × 109 NPs/ml | Citrate | HeLa | 105 kVp | 1.66 |
| Coulter et al. ( | 1.9 | 12 µM | Thiol | MDA-MB-231 | 160 kVp | 1.8 |
| Cui et al. ( | 2.7 | 0.5 mg/ml | Tiopronin | MDA-MB-231 | 225 kVp | 1.04–1.44 |
| Geng et al. ( | 14 | 1.25, 2.5, 5 nM | Glucose | SK-OV-3 | 90 kVp | 1.44 |
| Jain et al. ( | 1.9 | 12 µM | Thiol | MDA-MB-231 | 160 kVp | 1.41 |
| Jain et al. ( | 1.9 | 12 µM | Thiol | MDA-MB-231 | 160 kVp. | 1.41 |
| Joh et al. ( | 12 | 1 mM | PEG | U251 | 150 kVp | 1.3 |
| Kaur et al. ( | 5–9 | 5.5 µmol/mL | Glucose | HeLa | Gamma (60-Co) | 1.52 |
| Khoshgard et al. ( | 47–52 | 50 µM | PEG, Folate-conjugated | HeLa | Gamma (60-Co) | 1.64 (targeted) |
| Kong et al. ( | 10.8 | 15 µM | Cysteamine/glucose | MCF-7 | 200 kVp | 1.3 (cysteamine) |
| Liu et al. ( | 6.1 | 0.4–1 mM | PEG | EMT-6 | 6.5 keV | 2–45% decrease in survival rate |
| Liu et al. ( | 4.7 | 500 µM | PEG | CT26 | 6 MV | 1.33–1.59 |
| Liu et al. ( | 14.8 | 1.5–15 µg/ml | Citrate | HeLa | 50 kVp | 1.14–2.88 |
| Ngwa et al. ( | 50 | 0.2 mg/ml | Methyl polymer | HeLa | I-125 seeds with average photon energy of 28 keV | 1.7–2.3 |
| Rahman et al. ( | 1.9 | 0.25, 0.5, 1 mM | Thiol | BAEC | 80 Kvp | 20 |
| Roa et al. ( | 10.8 | 15 nM | Glucose | DU-145 | 662 keV (137-Cs) | 1.24–1.38 |
| Taggart et al. ( | 1.9 | 12 µM (500 µg/ml) | Thiol | MDA-MB-231 | 225 kVp | 1.17–1.23 |
| Wang et al. ( | 13 | 20 nM | Glucose | A549 | 6 MV | 1.49 |
| Wang et al. ( | 16 | 20 nM | Glucose | MDA-MB-231 | 6 MV | 1.49 (16 nm) |
| Wolfe et al. ( | 31 × 9 | 0.3 OD | PEG, goserelin-conjugated nanorods | PC-3 | 6 MV | 1.36 (targeted) |
| Zhang et al. ( | 30 | 15 nM | Glucose | DU-145 | 200 kVp | >1.3 |
| Zhang et al. ( | 4.8 | 0.05 mM | PEG | HeLa | 662 keV (137-Cs) | 1.41 (4.8 nm) |
| Zhang et al. ( | <2 | 50 µg/ml | GSH or BSA | HeLa | 662 keV (137-Cs) | 1.3 (GSH) |
| In vivo | ||||||
| Chang et al. ( | 13 | 200 µl, 200 nM GNPs IV | Citrate | B16F10 | 6 MeV e− | Tumour growth delay |
| Chattopadhyay et al. ( | 30 | 0.8 mg Au | PEG, HER2 Targeted | MDA-MB-361 | 100 kVp, 11 Gy | Tumour growth inhibition |
| Chen et al. ( | 28 | 1.3 mg/mL | BSA | U87 | 160 kVp, 3 Gy @ 2 h post injection, 2 Gy @ 24 h post injection | Tumour regression |
| Hainfeld et al. ( | 1.9 | 1.35 g Au/kg, | Thiol | EMT-6 | 250 kVp, | 50% and 86% long-term survival at 1.35 g and 2.7 g Au/kg |
| Hainfeld et al. ( | 1.9 | 1.9 g/kg | Thiol | SCCVII | 68 keV, | Increase median survival (53 vs 76 days and 31 vs 49 days at 68 keV and 157 keV) |
| Hainfeld et al. ( | 1.9 | 4 g Au/kg | Thiol | Tu-2449 | 100 kVp, 30 Gy | 50% long-term tumour free survival |
| Joh et al. ( | 12 | 1.25 g Au/kg | PEG | U251 | 175 kVp, 20 Gy | Increased median survival (28 vs 14 days) |
| Miladi et al. ( | 6.6 | 50 µl, 50 mM | DTDTPA, DTDTPA-Gd | U87 | Mean energy of 90 keV | DTDTPA increased lifespan up to 117.9% |
| Wolfe et al. ( | 31 x 9 | 100 µl, 40 µM GNPs | PEG | PC3 | 6 MV | Tumour growth delay |
| Zhang et al. ( | 4.8 | 4 mg/kg | PEG | HeLa | 662 keV | Tumour growth inhibition |
| Zhang et al. ( | <2 | 10 mg/kg | GSH or BSA | U14 | 662 keV | 55% (GSH) and 38% (BSA) decrease in tumour volume |
Comparison between GNPs’ radiosensitizing effect obtained with different energy sources, cell models and NP characteristics